NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...
H.C. Wainwright lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $12 from $22 and keeps a Buy rating on the shares. The firm is pushing back the time to U.S. market entry for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback